Integra Lifesciences Holdings Corp  (IART)
Other Ticker:  
Price: $38.6800 $-0.87 -2.200%
Day's High: $39.5 Week Perf: -0.05 %
Day's Low: $ 38.63 30 Day Perf: 8.87 %
Volume (M): 430 52 Wk High: $ 60.69
Volume (M$): $ 16,632 52 Wk Avg: $47.70
Open: $39.39 52 Wk Low: $33.44

 Market Capitalization (Millions $) 3,087
 Shares Outstanding (Millions) 80
 Employees 4,500
 Revenues (TTM) (Millions $) 1,543
 Net Income (TTM) (Millions $) 101
 Cash Flow (TTM) (Millions $) -238
 Capital Exp. (TTM) (Millions $) 57

Integra Lifesciences Holdings Corp
Integra Lifesciences Holdings Corp is a leading global medical technology company that produces a wide range of innovative and advanced surgical products and devices. The company provides products and solutions for orthopedic and tissue regeneration surgeries, neurosurgery, reconstructive and general surgery, and wound care. Founded in 1989, Integra Lifesciences is headquartered in Plainsboro, New Jersey, and operates in more than 100 countries worldwide.

Products and Services:

The company produces a broad range of surgical products and devices, including:

1. Orthopedic Products: These products are used to treat and repair musculoskeletal injuries, including fractures, soft tissue injuries, and degenerative conditions. Integra Lifesciences offers a range of bone graft substitutes, fixation systems, and instruments for orthopedic surgeons.

2. Tissue Regeneration Products: These products are used to repair and regenerate tissues including skin, bone, and nerves. Integra Lifesciences offers advanced solutions for tissue engineering, wound care, and regenerative medicine.

3. Neurosurgical Products: These products are used in neurosurgery to treat conditions such as brain tumors, skull base surgery, and spinal surgery. Integra Lifesciences provides a diverse range of neurosurgical devices, including cranial fixation systems, neurosurgical instruments, and neuro-monitoring products.

4. Reconstructive and General Surgery Products: These products are used in procedures to restore function and aesthetic appearance after traumatic injuries, cancers or other diseases. Integra Lifesciences provides devices and products for reconstructive surgery of the breast, face, and abdomen.

Operating Segments:

Integra Lifesciences operates through three main segments:

1. Codman Specialty Surgical: This segment is focused on neurosurgery and provides devices and instruments for cranial, spinal, and peripheral nerve surgical procedures.

2. Orthopedics and Tissue Technologies: This segment provides products and devices for orthopedics, wound care, and tissue regeneration.

3. Private Label: This segment provides a range of surgical instruments, such as ear, nose, and throat (ENT) instruments, and surgical implants and equipment to medical device companies.


Over the years, Integra Lifesciences has made several strategic acquisitions to enhance its product portfolio and expand its market reach. In 2017, the company acquired Codman Neurosurgery from Johnson & Johnson for $1.05 billion, which includes a portfolio of surgical instruments and devices for neurosurgery.

In 2014, Integra Lifesciences acquired the Derma Sciences wound care business to expand its portfolio of wound care solutions. In 2012, the company bought Ascension Orthopedics, a manufacturer of implants for upper extremity surgical procedures.


Integra Lifesciences is a leading global medical technology company that offers a wide range of innovative and advanced surgical products and devices. The company's products help surgeons and healthcare professionals to improve patient outcomes and quality of life. With a strong focus on research and development, manufacturing expertise, and global distribution network, Integra Lifesciences is well-positioned to continue providing innovative solutions for the medical industry.

   Company Address: 1100 Campus Road Princeton 8540 NJ
   Company Phone Number: 275-0500   Stock Exchange / Ticker: NASDAQ IART
   IART is expected to report next financial results on February 21, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Nocturne Acquisition Corporation

MBTCUs Scores Big in Third Quarter of 2023, Replicating Last Year's Success

Nocturne Acquisition Corporation, a reputable player in the financial industry, recently announced its earnings for the third quarter of 2023. While the results indicate increased deficits per share compared to the previous year, it is important to consider the broader context and acknowledge positive shifts that may impact future financial performance. This article will explore the implications of these results and shed light on the potential for a bullish outlook for Nocturne Acquisition Corporation.
Increased Deficits Per Share:
The most notable aspect of the Q3 2023 earnings report is the increase in deficits per share. Nocturne Acquisition Corporation experienced a deficit per share of $-0.11, as opposed to $-0.03 from the preceding year. This indicates a decline in profitability on a per-share basis. Additionally, the deficit grew from $-0.02 per share in the preceding reporting season. These numbers suggest that Nocturne Acquisition Corporation faced challenges during this period.

Becton Dickinson And Company

Medical Equipment and Supplies Company Witnesses Alarming Plunge in Earnings per Share Amidst Recent Fiscal Period

Becton Dickinson And Company, a medical equipment and supplies company, recently released its financial results for the fourth quarter of 2023. The company reported an income per share of $0.37 and revenue of $4.88 billion during this period. While the revenue increased by 20.459% compared to the fourth quarter of 2022, the company's income per share declined from $0.92 to $0.37. This indicates that although Becton Dickinson And Company saw significant revenue growth, their profitability decreased.
However, when compared to other companies in the Medical Equipment and Supplies sector, Becton Dickinson And Company had a much higher top-line improvement during the fourth quarter of 2023. On average, companies in this sector reported a top-line improvement of 4.80% in comparison to the same period in 2022. In contrast, Becton Dickinson And Company experienced a revenue surge of 20.459%. This suggests that the company outperformed its industry peers in terms of revenue growth.

Iridex Corp

IRIX Triumphs Over Obstacles, Shines in Q3 Earnings Season

Iridex Corp, a leading medical equipment and supplies company, recently released its financial results for the third quarter of 2023 earnings season. While the company reported a net loss of $-0.11 per share, this is an improvement compared to the previous year's loss of $-0.17 per share. However, the revenue for the quarter declined significantly by -12.718% to $12.62 million, compared to $14.46 million in the same period a year ago.
This decline in revenue is in stark contrast to the overall trend in the Medical Equipment and Supplies sector, which saw a top-line gain during the same period. The company's management has not provided specific reasons for this decline, but some experts speculate that it may be due to slowing demand or other market factors.

Digital Health Acquisition Corp

Breaking News: Medical Equipment Company Minimizes Losses, Records Remarkable Progress with $-1.13M in Recent Fiscal Period

/>In the medical equipment and supplies sector, industry analysts are closely scrutinizing the third quarter financial performance of Digital Health Acquisition Corp (DHAC). With a reported operating loss of $-0.518084 million, the company has yet to disclose any top-line figures for the July to September 2023 reporting season. However, the current results reflect a significant improvement compared to the same period in 2022, where the operating loss stood at $-1.129361 million. This development serves as a key indicator for the company's overall situation.
Growing Importance of Cost-Effectiveness in the Market:
For emerging growth entities such as DHAC, developing sustainable revenue sources is crucial to advancing to the next phase. Consequently, cost-effectiveness has become a vital aspect for these companies to remain competitive in the industry. Despite DHAC's efforts to prompt revenue sources, it is noteworthy that the company achieved not only a net profit of $0.078 million but also outperformed its Q3 2022 results.

Nuo Therapeutics Inc

Strong Third-Quarter Performance Positions Nuo Therapeutics Inc. as a Dominant Player in Medical Equipment and Supplies Industry

Nuo Therapeutics Inc: A Bullish Outlook for Future Growth
Nuo Therapeutics Inc, a leading Medical Equipment and Supplies company, recently reported third-quarter earnings that exceeded industry expectations. With a remarkable revenue rise of 507.166% year on year to $0.23 million, Nuo Therapeutics has demonstrated its robustness and resilience in the market. Although the company experienced a loss at $-0.02 per share, its strong revenue growth far outweighs this setback.
When compared to its industry peers, Nuo Therapeutics has clearly outperformed. The Medical Equipment and Supplies industry, as a whole, has averaged a revenue increase of just 4.80% during the same period. This significant gap in revenue growth showcases Nuo Therapeutics' ability to outshine its competitors and solidify its position as a market leader.


Integra Lifesciences Holdings's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com